title: alpha(1)-adrenoceptor-induced trafficking of aquaporin-5 to the apical plasma membrane of rat parotid cells.
abstract: Incubation of rat parotid tissue with 10 microM epinephrine resulted in a transient and marked trafficking of aquaporin-5 (AQP5) from intracellular membranes to the apical plasma membrane (APM) that was maximal at 1 min. This effect of epinephrine was mimicked by phenylephrine, but not by clonidine, dobutamine, or salbutamol, and it was inhibited by phentolamine, but not by propranolol. Furthermore, the epinephrine-induced trafficking of AQP5 was inhibited by phospholipase C inhibitor U73122 as well as dantrolene and TMB-8, both of which inhibit the release of Ca(2+) from intracellular stores. Cytochalasin D and tubulozole-C also inhibited this action of epinephrine. These results indicate that epinephrine, acting at alpha(1)-adrenoceptors, induces the trafficking of AQP5 to the APM by triggering the release of Ca(2+) from intracellular stores through inositol 1,4,5-trisphosphate and ryanodine receptors. In addition, the potent involvement of the cytoskeleton was shown in the epinephrine-induced trafficking of AQP5.
authors.affiliation: Department of Pharmacology, Tokushima University School of Dentistry, Kuramoto-cho, Tokushima, 770-8504, Japan. isikawa@dent.tokushimau.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: M T
authors.initials: MT
authors.lastname: Skowronski
authors.forename: N
authors.initials: N
authors.lastname: Inoue
authors.forename: H
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D051402:Aquaporin 5; D020346:Aquaporins / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology*; D004837:Epinephrine / Q000494:pharmacology; D004963:Estrenes / Q000494:pharmacology; D053496:Inositol 1,4,5-Trisphosphate Receptors; D007700:Kinetics; D008297:Male; D008565:Membrane Proteins; D010306:Parotid Gland / Q000187:drug effects / Q000502:physiology*; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000502:physiology; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000502:physiology; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; C496040:Aqp5 protein, rat; D051402:Aquaporin 5; D020346:Aquaporins; D015220:Calcium Channels; D004963:Estrenes; D053496:Inositol 1,4,5-Trisphosphate Receptors; D008565:Membrane Proteins; D011760:Pyrrolidinones; D018340:Receptors, Adrenergic, alpha-1; D018160:Receptors, Cytoplasmic and Nuclear; D019837:Ryanodine Receptor Calcium Release Channel; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D010656:Phenylephrine; D010738:Type C Phospholipases; D002118:Calcium; D004837:Epinephrine; D010646:Phentolamine